Bright Minds Biosciences Valuation Multiples

Bright Minds Biosciences Overview

About Bright Minds Biosciences

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Founded

2019

HQ

Employees

1

Website

brightmindsbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($34M)

EV

$710M

Valuation Multiples

Multiples.vc

Start free trial

Bright Minds Biosciences Financials

Bright Minds Biosciences reported last 12-month revenue of — and negative EBITDA of ($34M).

In the same LTM period, Bright Minds Biosciences generated — in gross profit, ($34M) in EBITDA losses, and had net loss of ($25M).

Bright Minds Biosciences P&L

In the most recent fiscal year, Bright Minds Biosciences reported revenue of — and EBITDA of ($10M).

Bright Minds Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bright Minds Biosciences Stock Performance

Bright Minds Biosciences has current market cap of $775M, and enterprise value of $710M.

Bright Minds Biosciences' stock price is $79.15.

Bright Minds Biosciences Valuation Multiples

Bright Minds Biosciences trades at (21.0x) EV/EBITDA.

Bright Minds Biosciences Financial Valuation Multiples

As of March 18, 2026, Bright Minds Biosciences has market cap of $775M and EV of $710M.

Equity research analysts estimate Bright Minds Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bright Minds Biosciences has a P/E ratio of (31.0x).

Bright Minds Biosciences Margins & Growth Rates

Bright Minds Biosciences' revenue in the last fiscal year grew by —.

Bright Minds Biosciences' revenue per employee in the last FY averaged $0.0M.

Bright Minds Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Bright Minds Biosciences M&A Activity

Bright Minds Biosciences acquired XXX companies to date.

Last acquisition by Bright Minds Biosciences was on XXXXXXXX, XXXXX. Bright Minds Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bright Minds Biosciences Investment Activity

Bright Minds Biosciences invested in XXX companies to date.

Bright Minds Biosciences made its latest investment on XXXXXXXX, XXXXX. Bright Minds Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).